

Investor Conference 2025



科妍生物科技股份有限公司
SciVision Biotech Inc.

Dr. Chun Chang Chen

Disclaimer

This slide contains our business prospect, financial condition and sales prognosis which are derived from our existing internal/external data analysis. The actual result of operations may differ from the expressed or implied in these forward-looking statements due to various reasons, including but not limited to price fluctuation, competition, global economic condition, exchange rate fluctuation, market demand or other risks that beyond our control.

The forward-looking statements in this release reflect the current belief of SciVision at this point and SciVision undertakes no obligation to update these statements with new information or future events.

Outline

1. **Company & Product & Technology Overview**
2. Business Operation

About SciVision Biotech Inc.



SciVISION
BIOTECH INC.


- Established in 2001
- Listed on TSE in 2013 (Code: 1786)
- Professional, high-class, pharmaceutical-grade Hyaluronic Acid medical device production
- Two factories are located at No. 1, S. 1st Rd., and No. 9, S. 6th Rd., Qianzhen Dist., Kaohsiung City, Taiwan
- Received certificates of QMS and ISO 13485 and complied with the regulations of the US FDA PIC/s GMP, etc.




Core Technologies I

Crosslinked Hyaluronic Acid Platform, CHAP®


The application of CHAP technology can be made into products of various types and applications



- Absorbable adhesion barrier




- Single-injection viscosupplement



- Dermal filler



- Other new application category products



Intellectual Property Protection of CHAP

US09371402B2

(12) **United States Patent**
Chen et al.

(10) **Patent No.:** US 9,371,402 B2
(45) **Date of Patent:** Jun. 21, 2016

(54) **METHOD FOR PRODUCING CROSS-LINKED HYALURONIC ACID**

(75) **Inventors:** Tor-Chern Chen, Kuo-Shiang (TW); Li-Sze Chen, Kuo-Shiang (TW)

(73) **Assignee:** SCIVISION BIOTECH INC., K.E.P.Z. (TW)

(*) **Notice:** Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 351 days.

(21) **Appl. No.:** 13/316,840
(22) **Filed:** Dec. 12, 2011
(65) **Prior Publication Data**
US 2012/0095286 A1 Apr. 19, 2012

Related U.S. Application Data
(63) Certification of part of application No. 12/385,502, filed on Apr. 9, 2009, now abandoned.

(51) **Int. Cl. Class.** C08B 37/08 (2006.01)
(52) **U.S. Cl. Class.** C08B 37/0972 (2013.01)
(58) **Field of Classification Search**
CPC — C08B 37/09, C08B 15/00, A61K 8/73, A61K 31/715
See application file for complete search history.

(56) **References Cited**
U.S. PATENT DOCUMENTS

Tsai, A. & Frutkin, G. H. (2009). The science of hyaluronic acid dermal fillers. *Journal of Cosmetic and Laser Therapy*, 11(3), 35-42.*
Y. Tokita et al., Hydrolytic Degradation of Hyaluronic Acid, *Polymer Degradation and Stability*, 1995, pp. 269-273, vol. 48.
Hsu J.C.F. Nello et al., A Sensitive Fluorimetric Procedure for the Determination of Aliphatic Epoxide under Physiological Conditions, *Analytical Biochemistry*, 1981, pp. 151-157, vol. 115.
European Search Report for 09045618.2-115, which is a corresponding application, that also (US2007090293), and U.S. Pat. No. 4,716,154, EP 1838544, US 7006,346/137, EP 0919206, Imbibi et al., Characteristics of Hyaluronic Acid, *Journal of Polymer Science: Part A: Polymer Chemistry*, 1974, vol. 12, No. 1.
Tomihata K. et al., Prepart of low water content, U.S. Patent Application No. 2009-27194 JP 007-02002, and JP 01 English abstract of corresponding JP patent application.

United States

(12) 發明專利

(11) 發明專利公告

(11) 發明專利公告

(21) 申請案號: 20090113209.B
(22) 申請日: 2009.10.31
(23) 發明人: 柯新志, 柯新祥
(24) 發明人地址: 中華民國 90000
(25) 代理人: 柯新祥
(26) 代理人地址: 中華民國 90000
(27) 發明專利權人: 柯新志, 柯新祥
(28) 發明專利權人地址: 中華民國 90000
(30) 優先權: 中華民國 90000
(31) 優先權: 中華民國 90000
(32) 優先權: 中華民國 90000
(33) 優先權: 中華民國 90000
(34) 優先權: 中華民國 90000
(35) 優先權: 中華民國 90000
(36) 優先權: 中華民國 90000
(37) 優先權: 中華民國 90000
(38) 優先權: 中華民國 90000
(39) 優先權: 中華民國 90000
(40) 優先權: 中華民國 90000
(41) 優先權: 中華民國 90000
(42) 優先權: 中華民國 90000
(43) 優先權: 中華民國 90000
(44) 優先權: 中華民國 90000
(45) 優先權: 中華民國 90000
(46) 優先權: 中華民國 90000
(47) 優先權: 中華民國 90000
(48) 優先權: 中華民國 90000
(49) 優先權: 中華民國 90000
(50) 優先權: 中華民國 90000
(51) 發明名稱: 交聯透明質酸之製造方法
(52) 發明摘要: 本發明提供一種製造交聯透明質酸的方法。其包括在約 10°C 至約 30°C 的溫度下將具有羧基的透明質酸與交聯劑反應，以形成交聯透明質酸。本發明方法亦包括在反應後將交聯透明質酸純化。

China

發明專利說明書 公告本

(本說明書格式、欄外及加註者，請勿任意更改，並請依序填寫)

新申請案號: 97136520
新申請日期: 97.09.23
IPC 分類: C08B
C08J3/04 (2006.01)
C08L5/08 (2006.01)

一、發明名稱: (中文/英文)
交聯透明質酸之製造方法
METHOD FOR PRODUCING CROSS-LINKED HYALURONIC ACID

二、申請人: (共 1 人)
姓名或名稱: (中文/英文)
科新生物科技股份有限公司
SCIVISION BIOTECH INC.
代表人: (中文/英文)
柯新祥
HAN, KAI-CHENG
住居所或營業所地址: (中文/英文)
高雄市府前區高華加工出口區南六路9號
9, SOUTH 6TH RD., K.E.P.Z., TAIWAN, R.O.C.
圖 籍: (中文/英文)
中華民國 R.O.C.

Taiwan

EUROPEAN PATENT APPLICATION

(1) 申請案號: 09040018
(2) 申請日: 2009.10.31
(3) 發明人: 柯新志, 柯新祥
(4) 發明人地址: 中華民國 90000
(5) 代理人: 柯新祥
(6) 代理人地址: 中華民國 90000
(7) 發明專利權人: 柯新志, 柯新祥
(8) 發明專利權人地址: 中華民國 90000
(9) 發明專利權人地址: 中華民國 90000
(10) 發明專利權人地址: 中華民國 90000
(11) 發明專利權人地址: 中華民國 90000
(12) 發明專利權人地址: 中華民國 90000
(13) 發明專利權人地址: 中華民國 90000
(14) 發明專利權人地址: 中華民國 90000
(15) 發明專利權人地址: 中華民國 90000
(16) 發明專利權人地址: 中華民國 90000
(17) 發明專利權人地址: 中華民國 90000
(18) 發明專利權人地址: 中華民國 90000
(19) 發明專利權人地址: 中華民國 90000
(20) 發明專利權人地址: 中華民國 90000
(21) 發明專利權人地址: 中華民國 90000
(22) 發明專利權人地址: 中華民國 90000
(23) 發明專利權人地址: 中華民國 90000
(24) 發明專利權人地址: 中華民國 90000
(25) 發明專利權人地址: 中華民國 90000
(26) 發明專利權人地址: 中華民國 90000
(27) 發明專利權人地址: 中華民國 90000
(28) 發明專利權人地址: 中華民國 90000
(29) 發明專利權人地址: 中華民國 90000
(30) 發明專利權人地址: 中華民國 90000
(31) 發明專利權人地址: 中華民國 90000
(32) 發明專利權人地址: 中華民國 90000
(33) 發明專利權人地址: 中華民國 90000
(34) 發明專利權人地址: 中華民國 90000
(35) 發明專利權人地址: 中華民國 90000
(36) 發明專利權人地址: 中華民國 90000
(37) 發明專利權人地址: 中華民國 90000
(38) 發明專利權人地址: 中華民國 90000
(39) 發明專利權人地址: 中華民國 90000
(40) 發明專利權人地址: 中華民國 90000
(41) 發明專利權人地址: 中華民國 90000
(42) 發明專利權人地址: 中華民國 90000
(43) 發明專利權人地址: 中華民國 90000
(44) 發明專利權人地址: 中華民國 90000
(45) 發明專利權人地址: 中華民國 90000
(46) 發明專利權人地址: 中華民國 90000
(47) 發明專利權人地址: 中華民國 90000
(48) 發明專利權人地址: 中華民國 90000
(49) 發明專利權人地址: 中華民國 90000
(50) 發明專利權人地址: 中華民國 90000
(51) 發明專利權人地址: 中華民國 90000
(52) 發明專利權人地址: 中華民國 90000
(53) 發明專利權人地址: 中華民國 90000
(54) 發明專利權人地址: 中華民國 90000
(55) 發明專利權人地址: 中華民國 90000
(56) 發明專利權人地址: 中華民國 90000
(57) 發明專利權人地址: 中華民國 90000
(58) 發明專利權人地址: 中華民國 90000
(59) 發明專利權人地址: 中華民國 90000
(60) 發明專利權人地址: 中華民國 90000
(61) 發明專利權人地址: 中華民國 90000
(62) 發明專利權人地址: 中華民國 90000
(63) 發明專利權人地址: 中華民國 90000
(64) 發明專利權人地址: 中華民國 90000
(65) 發明專利權人地址: 中華民國 90000
(66) 發明專利權人地址: 中華民國 90000
(67) 發明專利權人地址: 中華民國 90000
(68) 發明專利權人地址: 中華民國 90000
(69) 發明專利權人地址: 中華民國 90000
(70) 發明專利權人地址: 中華民國 90000
(71) 發明專利權人地址: 中華民國 90000
(72) 發明專利權人地址: 中華民國 90000
(73) 發明專利權人地址: 中華民國 90000
(74) 發明專利權人地址: 中華民國 90000
(75) 發明專利權人地址: 中華民國 90000
(76) 發明專利權人地址: 中華民國 90000
(77) 發明專利權人地址: 中華民國 90000
(78) 發明專利權人地址: 中華民國 90000
(79) 發明專利權人地址: 中華民國 90000
(80) 發明專利權人地址: 中華民國 90000
(81) 發明專利權人地址: 中華民國 90000
(82) 發明專利權人地址: 中華民國 90000
(83) 發明專利權人地址: 中華民國 90000
(84) 發明專利權人地址: 中華民國 90000
(85) 發明專利權人地址: 中華民國 90000
(86) 發明專利權人地址: 中華民國 90000
(87) 發明專利權人地址: 中華民國 90000
(88) 發明專利權人地址: 中華民國 90000
(89) 發明專利權人地址: 中華民國 90000
(90) 發明專利權人地址: 中華民國 90000
(91) 發明專利權人地址: 中華民國 90000
(92) 發明專利權人地址: 中華民國 90000
(93) 發明專利權人地址: 中華民國 90000
(94) 發明專利權人地址: 中華民國 90000
(95) 發明專利權人地址: 中華民國 90000
(96) 發明專利權人地址: 中華民國 90000
(97) 發明專利權人地址: 中華民國 90000
(98) 發明專利權人地址: 中華民國 90000
(99) 發明專利權人地址: 中華民國 90000
(100) 發明專利權人地址: 中華民國 90000

EU

(12) 發明專利

(11) 發明專利公告

(11) 發明專利公告

(21) 申請案號: 09040018
(22) 申請日: 2009.10.31
(23) 發明人: 柯新志, 柯新祥
(24) 發明人地址: 中華民國 90000
(25) 代理人: 柯新祥
(26) 代理人地址: 中華民國 90000
(27) 發明專利權人: 柯新志, 柯新祥
(28) 發明專利權人地址: 中華民國 90000
(29) 發明專利權人地址: 中華民國 90000
(30) 發明專利權人地址: 中華民國 90000
(31) 發明專利權人地址: 中華民國 90000
(32) 發明專利權人地址: 中華民國 90000
(33) 發明專利權人地址: 中華民國 90000
(34) 發明專利權人地址: 中華民國 90000
(35) 發明專利權人地址: 中華民國 90000
(36) 發明專利權人地址: 中華民國 90000
(37) 發明專利權人地址: 中華民國 90000
(38) 發明專利權人地址: 中華民國 90000
(39) 發明專利權人地址: 中華民國 90000
(40) 發明專利權人地址: 中華民國 90000
(41) 發明專利權人地址: 中華民國 90000
(42) 發明專利權人地址: 中華民國 90000
(43) 發明專利權人地址: 中華民國 90000
(44) 發明專利權人地址: 中華民國 90000
(45) 發明專利權人地址: 中華民國 90000
(46) 發明專利權人地址: 中華民國 90000
(47) 發明專利權人地址: 中華民國 90000
(48) 發明專利權人地址: 中華民國 90000
(49) 發明專利權人地址: 中華民國 90000
(50) 發明專利權人地址: 中華民國 90000
(51) 發明專利權人地址: 中華民國 90000
(52) 發明專利權人地址: 中華民國 90000
(53) 發明專利權人地址: 中華民國 90000
(54) 發明專利權人地址: 中華民國 90000
(55) 發明專利權人地址: 中華民國 90000
(56) 發明專利權人地址: 中華民國 90000
(57) 發明專利權人地址: 中華民國 90000
(58) 發明專利權人地址: 中華民國 90000
(59) 發明專利權人地址: 中華民國 90000
(60) 發明專利權人地址: 中華民國 90000
(61) 發明專利權人地址: 中華民國 90000
(62) 發明專利權人地址: 中華民國 90000
(63) 發明專利權人地址: 中華民國 90000
(64) 發明專利權人地址: 中華民國 90000
(65) 發明專利權人地址: 中華民國 90000
(66) 發明專利權人地址: 中華民國 90000
(67) 發明專利權人地址: 中華民國 90000
(68) 發明專利權人地址: 中華民國 90000
(69) 發明專利權人地址: 中華民國 90000
(70) 發明專利權人地址: 中華民國 90000
(71) 發明專利權人地址: 中華民國 90000
(72) 發明專利權人地址: 中華民國 90000
(73) 發明專利權人地址: 中華民國 90000
(74) 發明專利權人地址: 中華民國 90000
(75) 發明專利權人地址: 中華民國 90000
(76) 發明專利權人地址: 中華民國 90000
(77) 發明專利權人地址: 中華民國 90000
(78) 發明專利權人地址: 中華民國 90000
(79) 發明專利權人地址: 中華民國 90000
(80) 發明專利權人地址: 中華民國 90000
(81) 發明專利權人地址: 中華民國 90000
(82) 發明專利權人地址: 中華民國 90000
(83) 發明專利權人地址: 中華民國 90000
(84) 發明專利權人地址: 中華民國 90000
(85) 發明專利權人地址: 中華民國 90000
(86) 發明專利權人地址: 中華民國 90000
(87) 發明專利權人地址: 中華民國 90000
(88) 發明專利權人地址: 中華民國 90000
(89) 發明專利權人地址: 中華民國 90000
(90) 發明專利權人地址: 中華民國 90000
(91) 發明專利權人地址: 中華民國 90000
(92) 發明專利權人地址: 中華民國 90000
(93) 發明專利權人地址: 中華民國 90000
(94) 發明專利權人地址: 中華民國 90000
(95) 發明專利權人地址: 中華民國 90000
(96) 發明專利權人地址: 中華民國 90000
(97) 發明專利權人地址: 中華民國 90000
(98) 發明專利權人地址: 中華民國 90000
(99) 發明專利權人地址: 中華民國 90000
(100) 發明專利權人地址: 中華民國 90000

Japan



Birth of Next-Generation Cross-linked Hyaluronic Acid Technology

Our company has obtained a Taiwan patent for the "METHOD OF MANUFACTURING AUTO-CROSSLINKED HYALURONIC ACID GEL AND PRODUCTS THEREOF," making us the only global enterprise capable of effectively producing medical-grade hyaluronic acid without adding any chemicals.

Core Technologies II


Development of Regenerative Medicinal Products

Developing regenerative medical materials of various types and materials that can induce tissue regeneration or enhance existing functions.



Currently, SciVision has developed :
such as Poly-L-lactic acid, Polycaprolactone, Hydroxyapatite, and collagen, and some related products have already been certified and launched on the market.


Core Products of SciVision




Facial Aesthetics



Geriatrics care



Surgery




Urinary



Market Research on Global Market Value and Growth Rate

Applied field	Items	Global market value in 2024	CAGR
Facial Aesthetics	Dermal Filler	6.5 billion	15.5 % (Collagen Stimulators Taiwan and China Market CAGR: 28%、33%)
Geriatrics Care	Synovial Fluid Supplement	4.7 billion	9.0 %
Surgery	Absorbable Adhesion Barrier	4.5 billion	9.8 %
Urinary	Intravesical Instillation	1.4 billion	5.3 %

1. 2025 China Medicine Aesthetic Regenerative Anti-aging Injectables Industry Overview; 2025年中國醫美再生抗衰注射劑產業概覽
2. Visco Supplementation Market, Size, Global Forecast 2024-2030, Industry Trends, Share, Growth, Insight, Impact of Inflation, Company Analysis
3. Increasing Awareness & Rising Adoption by Surgeons to Drive Growth in the Global Anti-Adhesion Products Market, According to New Report by Global Industry Analysts, Inc.
4. Interstitial Cystitis Drugs Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033



I. Facial Aesthetics

Catering for a wide range of consumer needs

Fill immediately

Stimulate collagen proliferation

Fill immediately +
Stimulate collagen proliferation

Cross-linked
Hyaluronic Acid

Poly-L-lactic acid

Polycaprolactone
Carboxymethyl
cellulose sodium

Poly-L-lactic acid
Cross-linked
hyaluronic acid



HA Dermal Filler

Monophasic Fillers (Gel type)



Product advantages

- ✓ High safety performance
- ✓ Smooth and natural
- ✓ Easy operation

Biphasic Fillers (Particle type)



Product advantages

- ✓ High safety performance
- ✓ Strong structural support
- ✓ Shift resistance
- ✓ Excellent viscoelasticity
- ✓ Sufficient active ingredients
- ✓ Good resistance to degradation

HA Facial Dermal Implant of SciVision



CHAP專利玻尿酸交聯
平台科技
創造術品體絕佳支撐性


舊式顆粒型玻尿酸
無法有效支撐架構

凝膠式玻尿酸
囊軟無支撐性



Generational Evolution of Hyaluronic Acid Facial Dermal Implant

First-generation HA Facial Dermal Implant




Polymers composed of high- and low-molecular-weight hyaluronic acid are manufactured by mixing these components in varying ratios, along with a cross-linking agent. However, this approach typically requires the use of large amounts of cross-linker and is prone to the formation of ineffective or non-functional cross-linked structures.

Second-generation HA Facial Dermal Implant



Through the natural entanglement and ordered arrangement of hyaluronic acid molecules, an optimal three-dimensional structure is formed, requiring only a minimal amount of cross-linking agent for stabilization.

Third-generation HA Facial Dermal Implant




In the manufacturing process, in addition to preserving the molecular entanglement technology, self-crosslinking techniques are further incorporated, enabling the amount of cross-linking agent required to be reduced to an extremely minimal level.

Next-Generation Cross-linked Hyaluronic Acid Facial Dermal Implant

**Second-generation
HA Facial Dermal
Implant**

Monophasic
(Gel type)



**Third-generation
HA Facial Dermal
Implant**

Aqavita

TWI 840941B
US 9371402 B2
JP 5340093 B2
EP 2236523B1
CN 101724164B

**TWI 387620B
JP7678850B2**

Biphasic
(Particle type)



Nostalgie



New Facille

Clinical Trials and Publications

1. A Guide to Cheek Augmentation: Single-Point Deep Injection of Hyaluronic Acid Filler at Midface in Close Proximity to Medial Suborbicularis Oculi Fat (SOOF) Area. *Journal of Cosmetics, Dermatological Sciences and Applications*. 2016 Jan 06(01):1-8.
2. Use of High-Resolution Ultrasound (HRU) in the Assessment of Deep Injections of CHAP-Hyaluronic Acid (CHAP-HA) Fillers for Midface Lift. *Journal of Cosmetics, Dermatological Sciences and Applications*. 2018 Jan 08(03):126-132.
3. Dual-Plane Injection Technique With Microscale Tumescent Solution for Asian Rhinoplasty. *Dermatol Surg*. 2021 Jul 1;47(7):1015-1016.
4. CHAP-hyaluronic acid (CHAP-HA) filler as an optimal candidate for forehead filler augmentation using a 3-point injection technique. *Journal of Cosmetics, Dermatological Sciences and Applications*. 2021 Jan 11(02):76-83.
5. A Comprehensive Review of Long-Term Safety and Effectiveness of FACILLE Modified Sodium Hyaluronate Gel for Injection over 3 Years. *Journal of Cosmetics, Dermatological Sciences and Applications*, 2023, 13, 1-15.

Safe and effective injections
around the eyes
High user satisfaction



Figure 3. Before (upper) and immediately after (lower) single point deep injection of HA filler (1ml on each side) for cheek augmentation using 27 G sharp needle. Satisfactory results were noted with minimal bruising. Left: Case 2, Right: Case 7.

High compatibility with
human tissues






Figure 4. High-resolution ultrasound imaging immediately after HA injection (a, d, g, i), at 2-Week (b, e, h, k) and 4-week (c, f, j, l) follow up. Hydration of the HA would occur (arrows), and the HA would appear to be more homogeneous and hypoechoic (arrowheads) and may become completely undetectable with the surrounding tissues in the 4th week follow up (i, l).

Developing safe injection
guidelines for high-risk areas



Guidelines for
forehead injection



Collagen Stimulator I - SciVision

Natural beauty over time

CREATEFILL Poly-L-Lactic Acid

Product Description

CREATEFILL is a poly-L-lactic acid (PLLA) implant, a sterile, non-pyrogenic product, which needs to be reconstituted with sterile injectable water to form a suspension before use. This suspension contains biocompatible and biodegradable PLLA, which can stimulate the growth of endogenous collagen and elastic fibers. This product can be metabolized in the body into carbon dioxide, water, and glucose, which are compatible with the human body.

TFDA Class III Medical Device License:
MOHW-MD-No. 008137

Indications

The product is indicated for correction of shallow to deep nasolabial fold contour deficiencies and other facial wrinkles for use in immune-competent subjects. The product is intended for restoration and/or correction of the signs of facial fat loss (lipoatrophy).



Similar product:
Galderma Sculptra


Product Comparison

Product	CREATEFILL 可麗媿	SCULPTRA 舒顏萃	AestheFill 艾麗斯	VIVABELLA 薇貝拉
Origin and Manufacturer	Taiwan (SciVision)	Italy (Galderma)	Korea (Regen)	Korea (VAIM)
Main ingredient	Poly-L-lactic acid (PLLA)	Poly-L-lactic acid (PLLA)	Poly-D,L-lactic acid (PDLLA)	Poly-D,L-lactic acid (PDLLA)
Excipient	CMC, Mannitol	CMC, Mannitol	CMC	Linear HA
Induces an inflammatory response ^{1,3}	Mild	Mild	Medium	Medium
Collagen hyperplasia effect ¹	Better	Better	Medium	Medium
PLA duration ²	Longer	Longer	Medium	Medium
Package	Vial	Vial	Vial	Vial

1. Chinese Chemical Letters 32 (2021) 577–582
2. Journal of Chemical and Pharmaceutical Research, 2015, 7(12):51-63
3. Summary of particle geometry in inflammasome (IL-1 β production) and cytotoxicity. Reprinted from Baranov et al.

Features of CREATEFILL PLLA Implant


The microspheres of CREATEFILL PLLA dissolve instantly, allowing the product to be prepared quickly and uniformly. They provide gentle yet sustained stimulation of fibroblasts, promoting long-term regeneration of collagen and the extracellular matrix.





Fill immediately +
Stimulate collagen proliferation

Cross-linked hyaluronic acid composite
collagen stimulator



Composite Collagen Stimulator I

Stimulate collagen proliferation + Fill immediately
(Polycaprolactone) (Carboxymethyl cellulose sodium)

GIOVANIS Dermal Implant

Product Description

Giovanis Dermal Implant is a sterile, latex-free, thermo-causal, fully absorbable, non-permanent implant composed of Polycaprolactone (PCL) microparticles made from 30% polycaprolactone and a gel carrier made from 70% Phosphate Buffered Saline (PBS)-carboxymethylcellulose (CMC), which are FDA-approved MD materials. Carboxymethylcellulose (CMC), a biodegradable material, is used as the gel carrier, and the ingredients are all FDA-approved MD materials.

TFDA Class III Medical Device License:
MOHW-MD-No. 008320

Indications

M type: This product adds volume to moderate to severe facial depressions and provides temporary correction of facial lines.

S type: This product provides temporary correction of moderate to severe facial wrinkles and other imperfections in connective tissue or conditions.



Similar product:
AQTIS ELLANSE

Composite Collagen Stimulator II

Stimulate collagen proliferation + Fill immediately
(Poly-L-lactic acid) (Cross-linked Hyaluronic Acid)

ESKYLAGE Dermal Implant

Product Description

BELAROSY is primarily composed of poly-L-lactic acid (PLLA) microspheres suspended in a gel carrier consisting of cross-linked hyaluronic acid and phosphate-buffered saline. The presence of cross-linked hyaluronic acid allows for immediate improvement in facial volume and contour following injection. At the same time, the PLLA microspheres leverage the body's natural immune response to become encapsulated and stimulate connective tissue formation. Owing to their high biocompatibility, connective tissue typically develops over the course of several months, gradually replacing the gel carrier. Over time, areas of volume deficiency or contour irregularities are filled with the patient's own newly formed connective tissue.


Indications

This product is an injectable implant intended for subcutaneous implantation in the face to correct wrinkles, volume loss, and signs or conditions associated with facial aging. The inclusion of lidocaine provides a local anesthetic effect, helping to reduce discomfort during the treatment procedure.



Future Research Directions in Facial Aesthetics

Multifunctional composite products



hair
growth

Skin
rejuvenation

Skin
nourishment

Acne scar
treatment

Accelerate
wound healing



II. Geriatrics care



**Ultra-long-lasting
Synovial Fluid Supplement**
(1 injection for 12 months)



**Anti-free Radical Protective
Synovial Fluid Supplement**
(1 injection for 6 months)





**Long-lasting
Synovial Fluid Supplement**
(1 injection for 6 months)



**Triple Dose
Synovial Fluid Supplement**
(3 injections for 6 months)

Synovial Fluid Supplement


Product category	Treatment description	Global CAGR of treatments	Products
1-injection regimen (Long-acting)	Effect could be lasted for more than half a year with administrating 1 syringe.	12.4%	 <p>1 injection for 6 months 1 syringe per year Super Long-Acting Type Anti-free Radical Protection Type</p>
3-injection regimen	Effect could be lasted for half a year with administrating 3 syringes continuously, 1 syringe per week.	5.9%	 <p>Best-selling product in Taiwan</p>
5-injection regimen	Effect could be lasted for half a year with administrating 5 syringes continuously, 1 syringe per week.	5.5%	

Source: Joint Pain Injections Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)


Clinical Trials and Publications

1. The effect of three weekly intra-articular injections of hyaluronate on pain, function, and balance in patients with unilateral ankle arthritis. *J Bone Joint Surg Am.* 2011 Sep 21;93(18):1720-6.
2. Changes of synovial fluid protein concentrations in supra-patellar bursitis patients after the injection of different molecular weights of hyaluronic acid. *Exp Gerontol.* 2014 Apr;52:30-5.
3. Comparison of Single Intra-Articular Injection of Novel Hyaluronan (HYA-JOINT Plus) with Synvisc-One for Knee Osteoarthritis: A Randomized, Controlled, Double-Blind Trial of Efficacy and Safety. *J Bone Joint Surg Am.* 2017 Mar 15;99(6):462-471.
4. Origin and Efficacy of Hyaluronan Injections in Knee Osteoarthritis: Randomized, Double-Blind Trial. *Med Sci Monit.* 2018 Jul 9;24:4728-4737.
5. Improvement of self-reported functional scores and thickening of quadriceps and femoral intercondylar cartilage under ultrasonography after single intra-articular injection of a novel cross-linked hyaluronic acid in the treatment of knee osteoarthritis. *J Back Musculoskelet Rehabil.* 2018;31(4):709-718.
6. Safety and efficacy of single CHAP Hyaluronan injection versus three injections of linear Hyaluronan in pain relief for knee osteoarthritis: a prospective, 52-week follow-up, randomized, evaluator-blinded study. *BMC Musculoskelet Disord.* 2021 Jun 23;22(1):572.
7. Comparing efficacy of intraarticular single crosslinked Hyaluronan (HYAJOINT Plus) and platelet-rich plasma (PRP) versus PRP alone for treating knee osteoarthritis. *Sci Rep.* 2021 Jan 8;11(1):140.
8. Efficacy of Intra-Articular Injection of Biofermentation-Derived High-Molecular Hyaluronic Acid in Knee Osteoarthritis: An Ultrasonographic Study. *Cartilage.* 2022 Jan-Mar;13(1):19476035221077404.
9. Single Injection of Cross-Linked Hyaluronate in Knee Osteoarthritis: A 52-Week Double-Blind Randomized Controlled Trial. *Pharmaceutics.* 2022 Aug 25;14(9):1783.
10. Efficacy and safety of a single intra-articular injection of mannitol-combined hyaluronan in patients with knee osteoarthritis – A double-blinded randomized clinical study, *The Knee*, Volume 58, January 2026, 104292.

The pain relief effect is better than Sanofi's one-injection product



The thickness of the quadriceps and cartilage improved significantly at 3 and 6 months after surgery.



The effect can be maintained for more than one year, with high satisfaction.

Table 3 Patient satisfaction in time interval

Time	CHAP-HA (N=71)	Linear-HA (N=69)	P value
4th week	66.4 ± 22.4	68.4 ± 24.7	0.622
12th week	73.2 ± 23.4	71.1 ± 25.2	0.601
26th week	73.4 ± 22.7	63.5 ± 26.5	< 0.018 [†]
39th week	72.3 ± 22.4	52.1 ± 23.2	< 0.001 [†]
52th week	61.7 ± 22.0	37.5 ± 23.1	< 0.001 [†]

[†] indicates a significant difference between groups (P < 0.05)



Future Research and Development Direction

Drug-containing Synovial Fluid Supplement

Quick anti-inflammatory pain relief

Repair damaged cartilage

Strengthens body tissue protection
Prolong product efficacy

III. Absorbable Adhesion Barrier

Postsurgical adhesion

Injured organ
or tissue



Inflammation

The fibrin acts like
a glue to seal the injury



Adhesion
formation



Gynecologic surgery



Tendon, peripheral nerve, joint surgery

III. Absorbable Adhesion Barrier

For gynecological pelvic surgery



Product advantages

- ✓ High Biocompatibility
- ✓ Easy to apply
- ✓ Shift resistance

For ligament, peripheral nerve, joint surgery



Product advantages


- ✓ High Biocompatibility
- ✓ Easy to apply
- ✓ Shift resistance
- ✓ Long effective protection time

Clinical Trials and Publications

1. A resorbable hyaluronic acid hydrogel to prevent adhesion in porcine model under laparotomy pelvic surgery. *J Appl Biomater Funct Mater*. Jan-Dec 2021;19.
2. Crosslinked Hyaluronic Acid Gels for the Prevention of Intrauterine Adhesions after a Hysteroscopic Myomectomy in Women with Submucosal Myomas: A Prospective, Randomized, Controlled Trial. *Life*. 2020 May 15;10(5):67.
3. Efficacy of Applying Hyaluronic Acid Gels in the Primary Prevention of Intrauterine Adhesion after Hysteroscopic Myomectomy: A Meta-Analysis of Randomized Controlled Trials. *Life*. 2020 Nov 15;10(11):285.

Product could effectively avoid or slow down the occurrence of postoperative adhesions.

Product could effectively avoid or slow down the occurrence of postoperative adhesions and was significantly better than competing products.



	CHA-P Gel (n = 24)	CHA Gel (n = 23)	No (n = 23)	p-Value
Intrauterine Adhesion				
No	22 (91.7%) ^a	19 (82.6%) ^a	14 (60.9%)	0.031
Yes	2 (8.3%) ^a	4 (17.4%) ^a	9 (39.1%)	
Modified AFS Stage				
0	22 (91.7%) ^b	19 (82.6%) ^b	14 (60.9%)	0.014
I (mild)	2 (8.3%) ^b	3 (13.0%) ^b	1 (4.3%)	
II (moderate)	0 ^b	1 (4.3%) ^b	4 (17.4%)	
III (severe)	0 ^b	0 ^b	4 (17.4%)	

The data are presented as number (percentage). CHA-P (PROTAHERE absorbable adhesion barrier[®], SciVision Biotech Inc., Kaohsiung, Taiwan); CHA gel (Hyalobarrier[®] gel, Baxter, Pisa, Italy). No: no anti-adhesive agent gel treatment. AFS: American Fertility Society. ^a and ^b: The comparison between the CHA-P gel and CHA gel (^a: p-value = 0.352, ^b: p-value = 0.497).



Future Research and Development Direction

Composite wound care and anti-adhesion products


Expansion of
indications

Recovery of
bodily functions


Enhancement of
tissue protection

IV. Intravesical Instillation

HYAURO[®] Intravesical Instillation



HYAURO Intravesical Instillation



Product Specification

PACKAGE : 50 mL per vial

ACTIVE INGREDIENT: Sodium Hyaluronate 40mg

DESCRIPTION

The glycosaminoglycan (GAG) layer on the luminal surface of the bladder wall is the primary defense mechanism which can provide a protective barrier to against microorganisms, carcinogens, crystals and other agents present in the urine. HYAURO Intravesical Instillation has been developed to temporarily replenish the deficient GAG layer on the bladder epithelium.

INDICATION

The product is indicated for cystitis-associated GAG layer deficiency such as interstitial cystitis and cystitis caused by infection, trauma, urinary stones, urine retention, tumors and radiation.





Future Research and Development Direction


Drug-containing composite products

Fast-acting

Long-lasting effectiveness

Reduced recurrence risk


Core Products of SciVision




Facial Aesthetics



Geriatrics care



Surgery



Urinary



Outline


1. Company & Product & Technology Overview
- 2. Business Operation**

Our Vision




Science Creates Better Visions

Future Research and Development Direction



Cross-linked hyaluronic acid composite collagen stimulator




We will continue to develop **cross-linked hyaluronic acid composite products** in the future to expand product diversity.

II. Synovial Fluid Supplement



1 injection for 12 months



1 injection for 6 months
Anti-free Radical Protection Type




1 injection for 6 months



3 injections for 6 months


Core Products of SciVision




Facial Aesthetics



Geriatrics care



Surgery



Urinary



Outline

1. Company & Product & Technology Overview
- 2. Business Operation**

Profit & Loss-Consolidated

Profit & Loss-Consolidated


Unit: NT thousand dollars
(except for EPS)

	2025/01/01 ~ 2025/09/30 (Reviewed)		2024/01/01 ~ 2024/09/30 (Reviewed)		Annual growth rate
Revenue	635,232	100%	628,113	100%	1.1%
Cost of Goods Sold	(186,191)	-29%	(161,940)	-26%	15.0%
Gross Profit	449,041	71%	466,173	74%	-3.7%
Operating Expense	(309,050)	-49%	(278,290)	-44%	11.1%
Operating Income	139,991	22%	187,883	30%	-25.5%
Non-operating Income, Net	(27,347)	-4%	24,904	4%	-209.8%
Income before Tax	112,644	18%	212,787	34%	-47.1%
Net Income	99,154	16%	176,688	28%	-43.9%
EPS(NT\$)	1.38		2.08		

Domestic and International Sales Ratio


2025 Jan.-Sep. & 2024 Jan.- Sep.

2025/01/01~2025/09/30



■ Domestic ■ International



2024/01/01~2024/09/30



■ Domestic ■ International

Product Category Sales Ratio

2025 Jan.-Sep. & 2024 Jan.-Sep.



Balance Sheet-Consolidated

Balance Sheet-Consolidated

Unit:NT thousand dollars

	2025/09/30 (Reviewed)		2024/09/30 (Reviewed)	
Cash and Cash Equivalents	889,906	34%	568,808	26%
Accounts Receivable	130,536	5%	127,501	6%
Inventories	82,032	3%	76,517	4%
Financial Assets at Fair Value through Profit or Loss-Current	124,732	5%	63,716	3%
Financial Assets at Amortized Cost -Current	69,900	3%	149,900	7%
Other Current Assets	66,959	2%	30,726	1%
Total current assets	1,364,065	52%	1,017,168	47%
Property,Plant & Equipment	1,127,205	44%	1,096,448	52%
Other Non-Current Assets	118,597	4%	32,648	1%
Total non-current assets	1,245,802	48%	1,129,096	53%
Total Assets	2,609,867	100%	2,146,264	100%
Current Liabilities	179,951	7%	123,435	6%
Long-Term & Other Liabilities	509,322	20%	198,204	9%
Total Liabilities	689,273	26%	321,639	15%
Total Shareholders' Equities	1,920,594	74%	1,824,625	85%
Key Indices				
A/R Turnover (Days)	65.29		48.40	
Inventory Turnover (Days)	113.35		138.26	
Current Ratio(%)	758.02%		824.05%	
Net Profit Margin(%)	15.61%		28.13%	


Cash Flows-Consolidated

Cash Flows-Consolidated


<i>Unit:NT thousand dollars</i>	2025/01/01~2025/09/30 (Reviewed)	2024/01/01~2024/09/30 (Reviewed)
From Operating Activities	136,924	169,139
Profit before tax	112,644	212,787
Depreciation & Amortisation	58,156	46,968
Net change in working capital	(33,876)	(90,616)
From Investing Activities	(115,350)	58,812
Repayments of financial assets due at amortized cost	30,000	84,000
Capital expenditure	(82,255)	(25,201)
Net change in investing item	(63,095)	13
From Financing Activities	162,310	(170,244)
Issuance of bonds payable	400,000	0
Cash dividends	(233,871)	(169,328)
Net change in Fincncing item	(3,819)	(916)
Net Change in Cash	183,884	57,707
Beginning Balance	706,022	511,101
Ending Balance	889,906	568,808
Free Cash Flow	54,669	143,938

Healthy Cashflow and Expanding Profit


Revenue




Gross and Operating Margin



Net Profit



Cash Generated From Operations Before Interest And Taxes



Our Vision



Science Creates Better Visions